These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 3760186)

  • 1. Hypocalcemia may not be essential for the development of secondary hyperparathyroidism in chronic renal failure.
    Lopez-Hilker S; Galceran T; Chan YL; Rapp N; Martin KJ; Slatopolsky E
    J Clin Invest; 1986 Oct; 78(4):1097-102. PubMed ID: 3760186
    [TBL] [Abstract][Full Text] [Related]  

  • 2. 1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis.
    Brandi L
    Dan Med Bull; 2008 Nov; 55(4):186-210. PubMed ID: 19232159
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Marked suppression of secondary hyperparathyroidism by intravenous administration of 1,25-dihydroxy-cholecalciferol in uremic patients.
    Slatopolsky E; Weerts C; Thielan J; Horst R; Harter H; Martin KJ
    J Clin Invest; 1984 Dec; 74(6):2136-43. PubMed ID: 6549016
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dynamics of skeletal resistance to parathyroid hormone in the rat: effect of renal failure and dietary phosphorus.
    Bover J; Jara A; Trinidad P; Rodriguez M; Felsenfeld AJ
    Bone; 1999 Sep; 25(3):279-85. PubMed ID: 10495131
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A new analog of 1,25-(OH)2D3, 19-NOR-1,25-(OH)2D2, suppresses serum PTH and parathyroid gland growth in uremic rats without elevation of intestinal vitamin D receptor content.
    Takahashi F; Finch JL; Denda M; Dusso AS; Brown AJ; Slatopolsky E
    Am J Kidney Dis; 1997 Jul; 30(1):105-12. PubMed ID: 9214408
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The molecular basis of secondary hyperparathyroidism in chronic renal failure.
    Rahamimov R; Silver J
    Isr J Med Sci; 1994 Jan; 30(1):26-31. PubMed ID: 8138394
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Role of 1,25-dihydroxyvitamin D on the skeletal resistance to parathyroid hormone.
    Galceran T; Martin KJ; Morrissey JJ; Slatopolsky E
    Kidney Int; 1987 Dec; 32(6):801-7. PubMed ID: 3430963
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phosphorus accelerates the development of parathyroid hyperplasia and secondary hyperparathyroidism in rats with renal failure.
    Denda M; Finch J; Slatopolsky E
    Am J Kidney Dis; 1996 Oct; 28(4):596-602. PubMed ID: 8840952
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Autoregulation in the parathyroid glands by PTH/PTHrP receptor ligands in normal and uremic rats.
    Lewin E; Garfia B; Almaden Y; Rodriguez M; Olgaard K
    Kidney Int; 2003 Jul; 64(1):63-70. PubMed ID: 12787396
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Regulation of parathyroid cell gene expression in experimental uremia.
    Shvil Y; Naveh-Many T; Barach P; Silver J
    J Am Soc Nephrol; 1990 Jul; 1(1):99-104. PubMed ID: 2104257
    [TBL] [Abstract][Full Text] [Related]  

  • 11. No difference in intestinal strontium absorption after oral or IV calcitriol in children with secondary hyperparathyroidism. The European Study Group on Vitamin D in Children with Renal Failure.
    Ardissino G; Schmitt CP; Bianchi ML; Daccò V; Claris-Appiani A; Mehls O
    Kidney Int; 2000 Sep; 58(3):981-8. PubMed ID: 10972662
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hyperparathyroidism and 1,25-dihydroxyvitamin D deficiency in mild, moderate, and severe renal failure.
    Pitts TO; Piraino BH; Mitro R; Chen TC; Segre GV; Greenberg A; Puschett JB
    J Clin Endocrinol Metab; 1988 Nov; 67(5):876-81. PubMed ID: 3182962
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A calcimimetic agent lowers plasma parathyroid hormone levels in patients with secondary hyperparathyroidism.
    Goodman WG; Frazao JM; Goodkin DA; Turner SA; Liu W; Coburn JW
    Kidney Int; 2000 Jul; 58(1):436-45. PubMed ID: 10886592
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Calreticulin inhibits vitamin D's action on the PTH gene in vitro and may prevent vitamin D's effect in vivo in hypocalcemic rats.
    Sela-Brown A; Russell J; Koszewski NJ; Michalak M; Naveh-Many T; Silver J
    Mol Endocrinol; 1998 Aug; 12(8):1193-200. PubMed ID: 9717845
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of 24,25(OH)2D3 on PTH levels and bone histology in dogs with chronic uremia.
    Olgaard K; Finco D; Schwartz J; Arbelaez M; Teitelbaum S; Avioli L; Klahr S; Slatopolsky E
    Kidney Int; 1984 Dec; 26(6):791-7. PubMed ID: 6335904
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pathogenesis of secondary hyperparathyroidism.
    Slatopolsky E; Delmez JA
    Am J Kidney Dis; 1994 Feb; 23(2):229-36. PubMed ID: 8311080
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Reversal of secondary hyperparathyroidism by cimetidine in chronically uremic dogs.
    Jacob AI; Canterbury JM; Gavellas G; Lambert PW; Bourgoignie JJ
    J Clin Invest; 1981 Jun; 67(6):1753-60. PubMed ID: 7240419
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Secondary hyperparathyroidism and tertiary hyperparathyroidism chronic renal failure, uremia].
    Morio K; Koide K
    Nihon Rinsho; 1995 Apr; 53(4):958-64. PubMed ID: 7752492
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Skeletal resistance to endogenous parathyroid hormone in pateints with early renal failure. A possible cause for secondary hyperparathyroidism.
    Llach F; Massry SG; Singer FR; Kurokawa K; Kaye JH; Coburn JW
    J Clin Endocrinol Metab; 1975 Aug; 41(2):339-45. PubMed ID: 169280
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Regulation of parathyroid hormone synthesis in chronic renal failure in rats.
    Fukagawa M; Kaname S; Igarashi T; Ogata E; Kurokawa K
    Kidney Int; 1991 May; 39(5):874-81. PubMed ID: 2067203
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.